Nanomedicines for Dysfunctional Macrophage-Associated Diseases
Macrophages play vital functions in host inflammatory reaction, tissue repair, homeostasis and immunity. Dysfunctional macrophages have significant pathophysiological impacts on diseases such as cancer, inflammatory diseases (rheumatoid arthritis and inflammatory bowel disease), metabolic diseases (atherosclerosis, diabetes and obesity) and major infections like human immunodeficiency virus infection. In view of this common etiology in these diseases, targeting the recruitment, activation and regulation of dysfunctional macrophages represents a promising therapeutic strategy. With the advancement of nanotechnology, development of nanomedicines to efficiently target dysfunctional macrophages can strengthen the effectiveness of therapeutics and improve clinical outcomes. This review discusses the specific roles of dysfunctional macrophages in various diseases and summarizes the latest advances in nanomedicine-based therapeutics and theranostics for treating diseases associated with dysfunctional macrophages.
H. He et al., "Nanomedicines for Dysfunctional Macrophage-Associated Diseases," Journal of Controlled Release, vol. 247, pp. 106 - 126, Elsevier B.V., Feb 2017.
The definitive version is available at https://doi.org/10.1016/j.jconrel.2016.12.032
Chemical and Biochemical Engineering
Keywords and Phrases
Cell receptor; Drug delivery; Gene therapy; In vivo; Macrophage phenotype; Tissue macrophages
International Standard Serial Number (ISSN)
Article - Journal
© 2017 Elsevier B.V., All rights reserved.
10 Feb 2017
This work was supported by VCU's CTSA award (UL1TR000058) from the National Center for Advancing Translational Sciences and the CCTR Endowment Fund of Virginia Commonwealth University to HY and SG as well as National Science Foundation CAREER award (CBET0954957) (HY).